Evidence map›Paper›PMID 40634392›Full record

ArticleScientific reports2025

Basal-like subtype of esophageal adenocarcinoma and it's morphological, molecular and clinical characteristics.

Su Ir Lyu, Caroline Fretter, Axel M Hillmer, Bastian Grothey, Sascha Hoppe, Adrian Georg Simon, Thomas Zander, Karl Knipper, Wolfgang Schroeder, Christiane J Bruns and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Su Ir LyuFaculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany. su.lyu@uk-koeln.de.
Caroline FretterFaculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany.
Axel M HillmerFaculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany.
Bastian GrotheyFaculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany.
Sascha HoppeFaculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany.
Adrian Georg SimonFaculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany.
Thomas ZanderDepartment of Internal Medicine I, University Hospital Cologne, Medical Faculty, University of Cologne, Cologne, Germany.
Karl KnipperDepartment of General, Visceral and Cancer Surgery, Faculty of Medicine and University Hospital of Cologne, , University of Cologne, Cologne, Germany.
Wolfgang SchroederDepartment of General, Visceral and Cancer Surgery, Faculty of Medicine and University Hospital of Cologne, , University of Cologne, Cologne, Germany.
Christiane J BrunsDepartment of General, Visceral and Cancer Surgery, Faculty of Medicine and University Hospital of Cologne, , University of Cologne, Cologne, Germany.
Alexander QuaasFaculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal adenocarcinoma (EAC) and squamous cell carcinoma are the two main tumor types of the esophagus, each with distinct morphological and molecular features. While mixed adeno-squamous carcinomas are recognized, it remains unclear whether a basal-like subtype-known from breast and pancreatic adenocarcinomas-also exists in EAC. This study analyzed tumor samples from 953 patients with operable EAC for expression of the basal cytokeratins CK5 and CK6. Tumors with any squamous differentiation were excluded. A small subset (3.4%) showed a basal-like phenotype, characterized by high CK5 and/or CK6 expression and small-luminal tubular growth. High CK5 expression was associated with significantly worse overall survival, and within the neoadjuvantly treated subgroup, it emerged as an independent negative prognostic marker. Tumors with concurrent high CK5 and CK6 expression also showed reduced survival. Exploratory analyses revealed potential associations between CK6 expression and Claudin18.2 status, and between CK5 expression and Y-chromosome loss. These findings indicate the presence of a distinct basal-like subtype within EAC, linked to poor prognosis and possible molecular differences. CK5, alone or in combination with CK6, may serve as a practical biomarker for identifying this subtype and could support the development of more personalized treatment strategies.

Indexed as

AdenocarcinomaEsophageal NeoplasmsKeratin-5AdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisBiomarkers, TumorKeratin-5Basal-like subtypeCytokeratin 5Cytokeratin 6Esophageal adenocarcinomaPoor prognosis

Identifiers

PMID40634392
PMCPMC12241421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.